David Novak

Stock Analyst at Raymond James

(1.13)
# 3,674
Out of 4,955 analysts
9
Total ratings
44.44%
Success rate
-9.31%
Average return
Main Sectors:
Top Industries:

Stocks Rated by David Novak

Zymeworks
Dec 10, 2021
Downgrades: Outperform
Price Target: $74
Current: $14.42
Upside: +413.18%
Leap Therapeutics
Mar 2, 2021
Maintains: Outperform
Price Target: $25$35
Current: $0.28
Upside: +12,426.84%
Crescent Biopharma
Feb 4, 2021
Maintains: Outperform
Price Target: $300$270
Current: $14.14
Upside: +1,809.48%